What is KeyCorp’s Estimate for LFCR Q1 Earnings?

Lifecore Biomedical, Inc. (NASDAQ:LFCR) – Analysts at KeyCorp issued their Q1 2026 EPS estimates for Lifecore Biomedical in a research note issued to investors on Wednesday, September 3rd. KeyCorp analyst P. Knight expects that the company will post earnings of ($0.31) per share for the quarter. KeyCorp has a “Sector Weight” rating on the stock. The consensus estimate for Lifecore Biomedical’s current full-year earnings is ($0.91) per share. KeyCorp also issued estimates for Lifecore Biomedical’s Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.67) EPS and FY2027 earnings at ($0.46) EPS.

Other analysts also recently issued reports about the stock. William Blair initiated coverage on shares of Lifecore Biomedical in a research report on Wednesday, May 21st. They issued an “outperform” rating for the company. Wall Street Zen raised shares of Lifecore Biomedical from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. Two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, Lifecore Biomedical presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

Lifecore Biomedical Stock Performance

LFCR stock opened at $7.53 on Friday. The company has a quick ratio of 1.77, a current ratio of 2.84 and a debt-to-equity ratio of 113.76. The company has a market capitalization of $281.70 million, a price-to-earnings ratio of -5.75 and a beta of 0.64. Lifecore Biomedical has a 12 month low of $4.33 and a 12 month high of $8.85. The firm has a 50 day moving average of $7.62 and a two-hundred day moving average of $6.92.

Lifecore Biomedical (NASDAQ:LFCR) last posted its earnings results on Thursday, August 7th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.01). The business had revenue of $36.44 million during the quarter, compared to the consensus estimate of $35.36 million. Lifecore Biomedical had a negative return on equity of 846.51% and a negative net margin of 31.70%. Lifecore Biomedical has set its FY 2026 guidance at EPS.

Institutional Trading of Lifecore Biomedical

Large investors have recently modified their holdings of the company. GAMMA Investing LLC boosted its holdings in shares of Lifecore Biomedical by 1,839.7% during the 1st quarter. GAMMA Investing LLC now owns 3,569 shares of the company’s stock worth $25,000 after buying an additional 3,385 shares during the period. Summit Securities Group LLC acquired a new position in Lifecore Biomedical during the 1st quarter valued at $26,000. Hurley Capital LLC acquired a new position in Lifecore Biomedical during the 1st quarter valued at $35,000. State of Wyoming acquired a new position in Lifecore Biomedical during the 2nd quarter valued at $69,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Lifecore Biomedical during the 2nd quarter valued at $88,000. 83.36% of the stock is owned by institutional investors.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.